CAGE Bio Announces Positive Clinical Phase 2 Study Results for Atopic Dermatitis

  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us
  • More
    • Home
    • About Us
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisors
      • Partnerships
    • Our Technology
    • People
      • Our Team
      • Career
    • Patients
      • Clinical Trials
    • Media
      • Press Releases
      • In the news
      • Publications
    • Contact Us
  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us

In the news

Gene Silencing Therapy Stops the Itch of Psoriasis

A promising new approach for treating psoriasis — a topical lotion containing nucleic acids that transiently disrupt inflammatory gene activity. 

Novel Hand Sanitizer to Fight COVID-19

A new class of hand sanitizers for a new threat. 

Ionic liquid formulation delivers chemotherapy to tumors

A new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab. 

BioSpace

BioSpace

BioSpace

Biotech Startup Announces R&D Collaboration With Major Japanese Drug Delivery Company

FWBP

BioSpace

BioSpace

 Emerging  biotech company expands to HSC 

Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

Learn more